# US 2020/0347050 A1 · Tetrahydropyrazolopyrimidine compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0347050 A1
- Document ID: US20200347050A1
- Status: Published application
- Kind: A1
- Application number: 16/845,594
- Filed: 2020-04-10
- Published: 2020-11-05
- Earliest claimed: 2012-05-31
- Assignees: Eisai R&D Management Co., Ltd.
- Applicants: Eisai R&D Management Co., Ltd.
- Inventors: Roch BOIVIN; Eric CARLSON; Atsushi ENDO; Hans HANSEN; Lynn D. HAWKINS; Sally ISHIZAKA; Matthew MACKEY; Sridhar NARAYAN; Takashi SATOH; Shawn SCHILLER
- Web page: https://patentgrep.com/patent/US20200347050A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 487/04: Ortho-condensed systems
- Y02P 20/582: Recycling of unreacted starting or intermediate materials
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

## Claims

### Claim at position 1

1-48. (canceled)

### Claim 49

A method of preparing a compound of formula (I)
or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof or mixture of stereoisomers thereof, wherein
R1 is optionally substituted piperidinyl, optionally substituted pyridyl, optionally substituted pyrrolyl, optionally substituted pyrroldinyl, 1,4-dimethylthiazolyl, 2-ethyl-4-methylthiazolyl, 2-isopropylthiazol-5-yl, thiazolyl, 3-ethylthiazol-5-yl, 1-methylsulfonylpiperidin-4-yl, or
R1 is —C(O)Z, where Z is piperazinyl, (S)-2-(3-ethylpiperazin-1-yl), optionally substituted pyrrolopyrrolyl, piperidin-3-ylamino, or,
R1 is
where R13 is H, methylpyrazolyl, methylimidazolyl, benzyl, 3-hydroxybutyl, 3-(dimethylamino)-2,2-dimethylpropyl, ethylamide, methylpyridyl, methylsulfonyl, (1-methylimidazol-2-yl)methyl, (1,5-dimethylimidazol-4-yl)methyl, (1-methylpyrrol-2-yl)methyl, or where R13 is C(O)W, where W is —N(CH3)2, piperidinyl, piperazinyl, or morpholinyl, or,
R1 is
where R14 is —C(O)CH3, H or (1-methylpyrrol-2-yl)methyl, or,
R1 is
R1 is
where A, B, and D may all be carbon, or where two of A, B, and D are carbon and the other is nitrogen, or where one of A, B, and D is carbon and the remaining two are nitrogen; and when A is nitrogen R4 is absent, when B is nitrogen R2 is absent, and when D is nitrogen R3 is absent; and wherein
R2 is H, —CH3, or F, or, with R3 and the atoms at positions a and b, forms an optionally substituted pyridine or a pyrazole; and wherein
R3 is H, F, Cl, —CN, —CH3, —OCH3, —OH, —NH2, methylsulfonyl,
or, with R4 and the atoms at b and c, forms an optionally substituted benzene, optionally substituted imidazole, optionally substituted pyrazole, optionally substituted pyrazolidine, optionally substituted imidazolidine, optionally substituted isothiazole,
or, with R2 and the atoms at a and b, forms an optionally substituted pyridine or optionally substituted pyrazole; and wherein
R4 is F, —CN, —OCH3, —OEt, H, Cl, Br, —NH—C(O)—CH—(CH3)2, —N(CH3)2, —CH3, —CH2OH,
optionally substituted piperazinyl, 4-hydroxypiperizin-1-yl, optionally substituted piperidinyl not attached to a phenyl group through a nitrogen, or, with R3 and the atoms at b and c, forms an optionally substituted pyrazole ring or
or, with R5 and the atoms at c and d, forms an optionally substituted pyrazole ring or an optionally substituted pyrrole ring, or,
R4 is -(q)-C(O)X, where q is a bond, is —NH—, or is —CH2—, and
where X is —NR11R12,
where R11 and R12 are both H, both —CH2CH3, or both —CH3, or where one of R11 and R12 is H and the other is 1,1-dimethylethyl, cyclobutyl, cyclopropyl, lower alkyl, methyl alcohol, propyl alcohol, cyclobutylmethyl; 2,3-dihydroxypropyl, benzyl, azetidinyl, pyrrolidinyl, piperidinyl, methylazetidinyl, —CH2—NH—CH3, pyrazolyl, piperazinyl, alcohol, —OCH3, or
or
where X is optionally substituted pyrrolidinyl attached through a nitrogen to the carbonyl group of R4, optionally substituted piperidinyl not attached through a nitrogen to the carbonyl group of R4, optionally substituted pyrrolidinyl attached through a nitrogen to the carbonyl group of R4, optionally substituted piperazinyl attached through a nitrogen to the carbonyl group of R4, or optionally substituted morpholinyl attached through a nitrogen to the carbonyl group of R4,
and wherein
R5 is H, F, Cl, —CH3, —OCH3, pyrrolyl, —CH2OH, —NH2, —OH,
or, with R4 and the atoms at c and d, forms an optionally substituted benzene, an optionally substituted pyrazole, or an optionally substituted pyrrole, or, with R6 and the atoms at d and e, forms an optionally substituted pyridine, or R5 is C(O)Y, where Y is —NH2, —N(CH3)2, optionally substituted piperazinyl, optionally substituted piperidinyl,
and wherein
R6 is H, F, —CH3, —CF3, or, with R5 and the atoms at c and d, forms an optionally substituted benzene or an optionally substituted pyrazole; and wherein
R7 is —CF3 or —CHF2; and wherein
R8 is
and wherein
R9 is Br, Cl, F, I, or H;
with the following provisos:
when R4 is F: R2 is not —CH3 or F; R3 is not —CH3, —CN, F, Cl, or —OCH3; R5 is not —CH3, F, Cl, or —OCH3; and R6 is not —CH3 or F;
when R4 is Cl: R2 is not F; R3 is not F or —CN; R5 is not F, —CN, or —C(O)N(CH3)2, R6 is not —CF3 or F; D is not nitrogen; and either R5 is —C(O)NH2 or one of R2, R3, R5, and R6 is —CH3;
when R4 is —CH3: R3 is not F; R5 is not F; and R5 and R6 do not form a pyrimidine together with the atoms at d and e;
when R4 is —OCH3: R2 is not F; R3 is not Cl or —OCH3, R5 is not Cl or —OCH3; and R6 is not F or —CF3;
when R4 is —CN: R2 is not F; R3 is not Cl, F, or —OCH3, R5 is not Cl, F, or —OCH3; and R6 is not F;
when R4 is —OCH2CH3: R3 is not Cl or F; R5 is not Cl or F; and R6 is not —CF3;
when R4 is
R3 is not H or F; and R5 is not H or F;
when R4 is
at least one of R2, R3, R5, and R6 is not H;
when R4 is
R3 is not F; and R5 is not F;
when R2 is F: R3 is not —OCH3 or F; R5 is not —CN; and at least one of R3, R4, R5, and R6 is not H;
when R2 is Cl: R3 is not F;
when R2 is —CH3: R3 is not Cl; at least one of R3, R4, R5, and R6 is not —CH3; and R4 and R5 do not form a pyrazolyl with the atoms at c and d;
when R3 is —OCH3: R2 is not F; and R6 is not F;
when R3 is F: R2 is not —OCH3; and X is not
when R3 is Cl: R5 is not Cl; R11 is not benzyl; and R12 is not benzyl;
when R5 is Cl, R6 is not —CH3; R11 is not benzyl; and R12 is not benzyl;
when R5 is F or —OCH3: R6 is not F;
when R6 is F: at least one of R2, R3, R4, and R5 is not H;
when R3 and R5 are H: R11 is not cyclopropyl; and R12 is not cyclopropyl;
when R9 is Cl, R1 is not an amide group;
when B is nitrogen and A and D are carbon: R4 may not be —CN or
when R7 is —CHF2 and R4 is
then R4 does not have the absolute stereochemistry
and
wherein, when R8 is
then the following provisos are in effect:
when R4 is F: at least one of R2, R3, R5, and R6 is not H; R3 is not C(O)N(CH3)2; and R5 is not C(O)N(CH3)2;
when R4 is Cl: at least one of R2, R3, R5, and R6 is not H;
when R3 is F: R4 is not C(O)NHCH2CH2CH2CH3, C(O)N(CH3)2, C(O)NHCH2CH2CH3, or C(O)NHC(CH3)3;
R4 is not C(O)NHCH2CH2CH2OH, C(O)NHCH(CH3)2, —CN, or
R1 is not
R5 is not
R3 is not
when R2 is F: R5 is not —C(O)NH2;
when R2 is —CH3, R4 and R5 do not form a pyrazole with atoms at c and d; and
when B is nitrogen, R3 and R4 do not form an optionally substituted imidazole with the atoms at b and c; and
wherein, when R8 is
then following provisos are in effect:
R4 is not —CH3, —C(O)NHCH2CH2OH, —NHC(O)CH(CH3)2, or
when R4 is C(O)NHCH3, at least one of R2, R3, R5, and R6 is not H;
when R4 is —OCH3: R3 is not F or —CH3; and R5 is not F or —CH3;
when R4 is
R3 is not Cl; and R5 is not Cl;
when R4 is —C(O)NHCH(CH3)2 or —C(O)N(CH2CH3)2: at least one of R3 and R5 is not H;
R5 is not —C(O)NH2; and
R6 is not —CF3, comprising:
condensing a compound of formula III
and a compound of formula VI
in the presence of an organic acid to form a compound of formula VII
and reducing a compound of formula VII to form a compound of formula (I).

### Claim 50 (depends on 49)

The method of claim 49, further comprising isolating a compound of formula IX
and isolating a compound of formula X

### Claim 51 (depends on 49)

The method according to claim 49, wherein the compound of formula (I) is a compound of formula (IV),
or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof or mixture of stereoisomers thereof, wherein: R7a is H or F; and wherein
Ring A is:
wherein Y1 and Y2 are independently selected from the group consisting of —CH2— and —CH2CH2—, and wherein each of Y1 and Y2 is optionally substituted by C1-3 alkyl;
wherein X1, X2, and X3 are independently selected from the group consisting of —CH— and N;
wherein X1, X2, and X3 are independently selected from the group consisting of —CH— and N;
wherein X is N or —CH— optionally substituted by —CH3, F, or Cl, and
wherein R9 is —C(O)Z, wherein Z is 2,3-dihydroxypropylamine; a five to seven member cyclic diamine that is optionally bridged or optionally substituted at a carbon atom with a lower alkyl; a seven to ten member bicyclodiamine; a seven to eleven member spirodiamine; —NH substituted with a four to seven member cyclic amine optionally substituted with —NH2; —OH; —CH2NHR, wherein R is H or lower alkyl; —NH substituted with a seven to eleven member spiroalkane optionally substituted with —NH2; or
R9 is CH3NHC(O)—, and a carbon atom on the aryl ring to which R9 is attached is substituted with one of —CH3, F, or Cl; R9 is (CH3)2CHNHC(O)—, and a carbon atom on the aryl ring to which R9 is attached is substituted with one of —CH3, F, or Cl; or R9 is (CH3)3CNHC(O)— and a carbon atom on the aryl ring to which R9 is attached is substituted with one of —CH3, F, or Cl; or
R9 is
herein the piperazine is optionally bridged or substituted with lower alkyl and R10 is H or —CH3; or
R9 is
Wherein n is 1-3 and the cyclic diamine is optionally bridged or substituted with lower alkyl; or
R9 is
wherein n is 1-4; or
R9 is —NHC(O)NH2, —CH2C(O)NH— wherein the nitrogen is substituted with a four to seven member cyclic amine; —CH2—C(O)— wherein the carbonyl is substituted with a seven to ten member bicyclodiamine; and a four to seven member cyclic amine substituted with —CH2C(O)NH2; or
wherein X is N or —CH— wherein the C is optionally substituted by —CH3, F, or Cl, and wherein
R10 is —C(O)NH— wherein the nitrogen is substituted by a four to seven member cyclic amine; —C(O)— substituted by a seven to ten member bicyclodiamine; —C(O)— substituted by a seven to eleven member spirodiamine; pyrazole; [1,2,4]oxadiazole optionally substituted by —CH3 on a carbon atom of the oxadiazole; —NHC(O)CH3; —CH2— substituted by a piperazine; —CH2— substituted by a piperazine including a methyl substituent; —C(O)— substituted by a five to seven member cyclic diamine; —C(O)NHCH2— wherein the —CH2— is substituted by azetidine; or —C(O)— substituted with a five to seven member cyclic amine wherein the amine includes an —NH2 substituent; or
cyanophenyl; isoquinoline; cyclohexene substituted with —NH2 at the 4′ position; 1,4-dimethylindazole-5-yl; 1,6-dimethylindazole-5-yl; cyclohexene substituted with spiropiperidine at the 4′ position; 1-piperidinopyrazole; or o-methoxypyridine.

### Claim 52 (depends on 49)

The method according to claim 49, wherein the isolating is by chiral, high performance liquid chromatography or by diastereomeric crystallization.

### Claim 53 (depends on 49)

The method according to claim 49, wherein R8 is

### Claim 54

A method of preparing a compound of formula (I)
or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof or mixture of stereoisomers thereof, wherein
R1 is optionally substituted piperidinyl, optionally substituted pyridyl, optionally substituted pyrrolyl, optionally substituted pyrroldinyl, 1,4-dimethylthiazolyl, 2-ethyl-4-methylthiazolyl, 2-isopropylthiazol-5-yl, thiazolyl, 3-ethylthiazol-5-yl, 1-methylsulfonylpiperidin-4-yl, or
R1 is —C(O)Z, where Z is piperazinyl, (S)-2-(3-ethylpiperazin-1-yl), optionally substituted pyrrolopyrrolyl, piperidin-3-ylamino, or,
R1 is
where R13 is H, methylpyrazolyl, methylimidazolyl, benzyl, 3-hydroxybutyl, 3-(dimethylamino)-2,2-dimethylpropyl, ethylamide, methylpyridyl, methylsulfonyl, (1-methylimidazol-2-yl)methyl, (1,5-dimethylimidazol-4-yl)methyl, (1-methylpyrrol-2-yl)methyl, or where R13 is C(O)W, where W is —N(CH3)2, piperidinyl, piperazinyl, or morpholinyl, or,
R1 is
where R14 is —C(O)CH3, H, or (1-methylpyrrol-2-yl)methyl, or,
R1 is
R1 is
where A, B, and D may all be carbon, or where two of A, B, and D are carbon and the other is nitrogen, or where one of A, B, and D is carbon and the remaining two are nitrogen; and when A is nitrogen R4 is absent, when B is nitrogen R2 is absent, and when D is nitrogen R3 is absent; and wherein
R2 is H, —CH3, or F, or, with R3 and the atoms at positions a and b, forms an optionally substituted pyridine or a pyrazole; and wherein
R3 is H, F, Cl, —CN, —CH3, —OCH3, —OH, —NH2, methylsulfonyl,
or, with R4 and the atoms at b and c, forms an optionally substituted benzene, optionally substituted imidazole, optionally substituted pyrazole, optionally substituted pyrazolidine, optionally substituted imidazolidine, optionally substituted isothiazole,
or, with R2 and the atoms at a and b, forms an optionally substituted pyridine or optionally substituted pyrazole; and wherein
R4 is F, —CN, —OCH3, —OEt, H, Cl, Br, —NH—C(O)—CH—(CH3)2, —N(CH3)2, —CH3, —CH2OH,
optionally substituted piperazinyl, 4-hydroxypiperizin-1-yl, optionally substituted piperidinyl not attached to a phenyl group through a nitrogen, or, with R3 and the atoms at b and c, forms
an optionally substituted pyrazole ring or
or, with R5 and the atoms at c and d, forms an optionally substituted pyrazole ring or an optionally substituted pyrrole ring, or,
R4 is -(q)-C(O)X, where q is a bond, is —NH—, or is —CH2—, and
where X is —NR11R12,
where R11 and R12 are both H, both —CH2CH3, or both —CH3, or where one of R11 and R12 is H and the other is 1,1-dimethylethyl, cyclobutyl, cyclopropyl, lower alkyl, methyl alcohol, propyl alcohol, cyclobutylmethyl; 2,3-dihydroxypropyl, benzyl, azetidinyl, pyrrolidinyl, piperidinyl, methylazetidinyl, —CH2—NH—CH3, pyrazolyl, piperazinyl, alcohol, —OCH3, or
or
where X is optionally substituted pyrrolidinyl attached through a nitrogen to the carbonyl group of R4, optionally substituted piperidinyl not attached through a nitrogen to the carbonyl group of R4, optionally substituted pyrrolidinyl attached through a nitrogen to the carbonyl group of R4, optionally substituted piperazinyl attached through a nitrogen to the carbonyl group of R4, or optionally substituted morpholinyl attached through a nitrogen to the carbonyl group of R4,
and wherein
R5 is H, F, Cl, —CH3, —OCH3, pyrrolyl, —CH2OH, —NH2, —OH,
or, with R4 and the atoms at c and d, forms an optionally substituted benzene, an optionally substituted pyrazole, or an optionally substituted pyrrole, or, with R6 and the atoms at d and e, forms an optionally substituted pyridine, or R5 is C(O)Y, where Y is —NH2, —N(CH3)2, optionally substituted piperazinyl, optionally substituted piperidinyl,
and wherein
R6 is H, F, —CH3, —CF3, or, with R5 and the atoms at c and d, forms an optionally substituted benzene or an optionally substituted pyrazole; and wherein
R7 is —CF3 or —CHF2; and wherein
R8 is
and wherein
R9 is Br, Cl, F, I, or H;
with the following provisos:
when R4 is F: R2 is not —CH3 or F; R3 is not —CH3, —CN, F, Cl, or —OCH3; R5 is not —CH3, F, Cl, or —OCH3; and R6 is not —CH3 or F;
when R4 is Cl: R2 is not F; R3 is not F or —CN; R5 is not F, —CN, or —C(O)N(CH3)2, R6 is not —CF3 or F; D is not nitrogen; and either R5 is —C(O)NH2 or one of R2, R3, R5, and R6 is —CH3;
when R4 is —CH3: R3 is not F; R5 is not F; and R5 and R6 do not form a pyrimidine together with the atoms at d and e;
when R4 is —OCH3: R2 is not F; R3 is not Cl or —OCH3, R5 is not Cl or —OCH3; and R6 is not F or —CF3;
when R4 is —CN: R2 is not F; R3 is not Cl, F, or —OCH3, R5 is not Cl, F, or —OCH3; and R6 is not F;
when R4 is —OCH2CH3: R3 is not Cl or F; R5 is not Cl or F; and R6 is not —CF3;
when R4 is
R3 is not H or F; and R5 is not H or F;
when R4 is
at least one of R2, R3, R5, and R6 is not H;
when R4 is
R3 is not F; and R5 is not F;
when R2 is F: R3 is not —OCH3 or F; R5 is not —CN; and at least one of R3, R4, R5, and R6 is not H;
when R2 is Cl: R3 is not F;
when R2 is —CH3: R3 is not Cl; at least one of R3, R4, R5, and R6 is not —CH3; and R4 and R5 do not form a pyrazolyl with the atoms at c and d;
when R3 is —OCH3: R2 is not F; and R6 is not F;
when R3 is F: R2 is not —OCH3; and X is not;
when R3 is Cl: R5 is not Cl; R is not benzyl; and R12 is not benzyl;
when R5 is Cl, R6 is not —CH3; R is not benzyl; and R12 is not benzyl;
when R5 is F or —OCH3: R6 is not F;
when R6 is F: at least one of R2, R3, R4, and R5 is not H;
when R3 and R5 are H: R11 is not cyclopropyl; and R12 is not cyclopropyl;
when R9 is Cl, R1 is not an amide group;
when B is nitrogen and A and D are carbon: R4 may not be —CN or
when R7 is —CHF2 and R4 is
then R4 does not have the absolute stereochemistry
and
wherein, when R8 is
then the following provisos are in effect:
when R4 is F: at least one of R2, R3, R5, and R6 is not H; R3 is not C(O)N(CH3)2; and R5 is not C(O)N(CH3)2;
when R4 is Cl: at least one of R2, R3, R5, and R6 is not H;
when R3 is F: R4 is not C(O)NHCH2CH2CH2CH3, C(O)N(CH3)2, C(O)NHCH2CH2CH3, or C(O)NHC(CH3)3;
R4 is not C(O)NHCH2CH2CH2OH, C(O)NHCH(CH3)2, —CN, or
R1 is not
R5 is not
R3 is not;
when R2 is F: R5 is not —C(O)NH2;
when R2 is —CH3, R4 and R5 do not form a pyrazole with atoms at c and d; and
when B is nitrogen, R3 and R4 do not form an optionally substituted imidazole with the atoms at b and c; and
wherein, when R8 is
then following provisos are in effect:
R4 is not —CH3, —C(O)NHCH2CH2OH, —NHC(O)CH(CH3)2, or
when R4 is C(O)NHCH3, at least one of R2, R3, R5, and R6 is not H;
when R4 is —OCH3: R3 is not F or —CH3; and R5 is not F or —CH3;
when R4 is
R3 is not Cl; and R5 is not Cl;
when R4 is —C(O)NHCH(CH3)2 or —C(O)N(CH2CH3)2: at least one of R3 and R5 is not H;
R5 is not —C(O)NH2; and
R6 is not —CF3, comprising:
condensing a compound of formula IV
and a compound of formula VI
to form a compound of formula X
reacting a compound of formula X with a triflouromethylsulfonylation reagent to provide a compound of formula XI
and
(1) reducing a compound of formula XI to form a compound of formula XII
and subjecting a compound a formula XII to Suzuki cross-coupling conditions with a boronate
to form a compound of formula (I);
or
(2) subjecting a compound of formula XI to Suzuki cross-coupling conditions with a boronate
to form a compound of formula XIV
and reducing a compound of formula XIV to form a compound of formula (I).

### Claim 55 (depends on 54)

The method of claim 54, further comprising isolating a compound of formula IX
and isolating a compound of formula X

### Claim 56 (depends on 54)

The method according to claim 54, wherein the compound of formula (I) is a compound of formula (IV),
or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof or mixture of stereoisomers thereof, wherein: R7a is H or F; and wherein
Ring A is:
wherein Y1 and Y2 are independently selected from the group consisting of —CH2— and —CH2CH2—, and wherein each of Y1 and Y2 is optionally substituted by C1-3 alkyl;
wherein X1, X2, and X3 are independently selected from the group consisting of —CH— and N;
wherein X1, X2, and X3 are independently selected from the group consisting of —CH— and N;
wherein X is N or —CH— optionally substituted by —CH3, F, or Cl, and
wherein R9 is —C(O)Z, wherein Z is 2,3-dihydroxypropylamine; a five to seven member cyclic diamine that is optionally bridged or optionally substituted at a carbon atom with a lower alkyl; a seven to ten member bicyclodiamine; a seven to eleven member spirodiamine; —NH substituted with a four to seven member cyclic amine optionally substituted with —NH2—OH; —CH2NHR, wherein R is H or lower alkyl; —NH substituted with a seven to eleven member spiroalkane optionally substituted with —NH2; or
R9 is CH3NHC(O)—, and a carbon atom on the aryl ring to which R9 is attached is substituted with one of —CH3, F, or Cl; R9 is (CH3)2CHNHC(O)—, and a carbon atom on the aryl ring to which R9 is attached is substituted with one of —CH3, F, or Cl; or R9 is (CH3)3CNHC(O)— and a carbon atom on the aryl ring to which R9 is attached is substituted with one of —CH3, F, or Cl; or
R9 is
wherein the piperazine is optionally bridged or substituted with lower alkyl and R10 is H or —CH3; or
R9 is
wherein n is 1-3 and the cyclic diamine is optionally bridged or substituted with lower alkyl; or
R9 is
wherein n is 1-4; or
R9 is —NHC(O)NH2, —CH2C(O)NH— wherein the nitrogen is substituted with a four to seven member cyclic amine; —CH2—C(O)— wherein the carbonyl is substituted with a seven to ten member bicyclodiamine; and a four to seven member cyclic amine substituted with —CH2C(O)NH2: or
wherein X is N or —CH— wherein the C is optionally substituted by —CH3, F, or Cl, and wherein
R10 is —C(O)NH— wherein the nitrogen is substituted by a four to seven member cyclic amine; —C(O)— substituted by a seven to ten member bicyclodiamine; —C(O)— substituted by a seven to eleven member spirodiamine; pyrazole; [1,2,4]oxadiazole optionally substituted by —CH3 on a carbon atom of the oxadiazole; —NHC(O)CH3; —CH2— substituted by a piperazine; —CH2— substituted by a piperazine including a methyl substituent; —C(O)— substituted by a five to seven member cyclic diamine; —C(O)NHCH2— wherein the —CH2— is substituted by azetidine; or —C(O)— substituted with a five to seven member cyclic amine wherein the amine includes an —NH2 substituent; or
cyanophenyl; isoquinoline; cyclohexene substituted with —NH2 at the 4′ position; 1,4-dimethylindazole-5-yl; 1,6-dimethylindazole-5-yl; cyclohexene substituted with spiropiperidine at the 4′ position; 1-piperidinopyrazole; or o-methoxypyridine.

### Claim 57 (depends on 54)

The method according to claim 54, wherein the isolating is by chiral, high performance liquid chromatography or by diastereomeric crystallization.

### Claim 58 (depends on 54)

The method according to claim 54, wherein R8 is

### Claim 59

A method of preparing a compound of formula (I)
or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof or mixture of stereoisomers thereof, wherein
R1 is optionally substituted piperidinyl, optionally substituted pyridyl, optionally substituted pyrrolyl, optionally substituted pyrroldinyl, 1,4-dimethylthiazolyl, 2-ethyl-4-methylthiazolyl, 2-isopropylthiazol-5-yl, thiazolyl, 3-ethylthiazol-5-yl, 1-methylsulfonylpiperidin-4-yl, or
R1 is —C(O)Z, where Z is piperazinyl, (S)-2-(3-ethylpiperazin-1-yl), optionally substituted pyrrolopyrrolyl, piperidin-3-ylamino, or,
R1 is
where R13 is H, methylpyrazolyl, methylimidazolyl, benzyl, 3-hydroxybutyl, 3-(dimethylamino)-2,2-dimethylpropyl, ethylamide, methylpyridyl, methylsulfonyl, (1-methylimidazol-2-yl)methyl, (1,5-dimethylimidazol-4-yl)methyl, (1-methylpyrrol-2-yl)methyl, or where R13 is C(O)W, where W is —N(CH3)2, piperidinyl, piperazinyl, or morpholinyl, or,
R1 is
where R14 is —C(O)CH3, H, or (1-methylpyrrol-2-yl)methyl, or,
R1 is
or
R1 is
where A, B, and D may all be carbon, or where two of A, B, and D are carbon and the other is nitrogen, or where one of A, B, and D is carbon and the remaining two are nitrogen; and when A is nitrogen R4 is absent, when B is nitrogen R2 is absent, and when D is nitrogen R3 is absent; and wherein
R2 is H, —CH3, or F, or, with R3 and the atoms at positions a and b, forms an optionally substituted pyridine or a pyrazole; and wherein
R3 is H, F, Cl, —CN, —CH3, —OCH3, —OH, —NH2, methylsulfonyl,
or, with R4 and the atoms at b and c, forms an optionally substituted benzene, optionally substituted imidazole, optionally substituted pyrazole, optionally substituted pyrazolidine, optionally substituted imidazolidine, optionally substituted isothiazole,
or, with R2 and the atoms at a and b, forms an optionally substituted pyridine or optionally substituted pyrazole; and wherein
R4 is F, —CN, —OCH3, —OEt, H, Cl, Br, —NH—C(O)—CH—(CH3)2, —N(CH3)2, —CH3, —CH2OH,
optionally substituted piperazinyl, 4-hydroxypiperizin-1-yl, optionally substituted piperidinyl not attached to a phenyl group through a nitrogen, or, with R3 and the atoms at b and c, forms an optionally substituted pyrazole ring or
or, with R5 and the atoms at c and d, forms an optionally substituted pyrazole ring or an optionally substituted pyrrole ring, or,
R4 is -(q)-C(O)X, where q is a bond, is —NH—, or is —CH2—, and
where X is —NR11R12,
where R11 and R12 are both H, both —CH2CH3, or both —CH3, or where one of R11 and R12 is H and the other is 1,1-dimethylethyl, cyclobutyl, cyclopropyl, lower alkyl, methyl alcohol, propyl alcohol, cyclobutylmethyl; 2,3-dihydroxypropyl, benzyl, azetidinyl, pyrrolidinyl, piperidinyl, methylazetidinyl, —CH2—NH—CH3, pyrazolyl, piperazinyl, alcohol, —OCH3, or
or
where X is optionally substituted pyrrolidinyl attached through a nitrogen to the carbonyl group of R4, optionally substituted piperidinyl not attached through a nitrogen to the carbonyl group of R4, optionally substituted pyrrolidinyl attached through a nitrogen to the carbonyl group of R4, optionally substituted piperazinyl attached through a nitrogen to the carbonyl group of R4, or optionally substituted morpholinyl attached through a nitrogen to the carbonyl group of R4,
and wherein
R5 is H, F, Cl, —CH3, —OCH3, pyrrolyl, —CH2OH, —NH2, —OH,
or, with R4 and the atoms at c and d, forms an optionally substituted benzene, an optionally substituted pyrazole, or an optionally substituted pyrrole, or, with R6 and the atoms at d and e, forms an optionally substituted pyridine, or R5 is C(O)Y, where Y is —NH2, —N(CH3)2, optionally substituted piperazinyl, optionally substituted piperidinyl,
and wherein
R6 is H, F, —CH3, —CF3, or, with R5 and the atoms at c and d, forms an optionally substituted benzene or an optionally substituted pyrazole; and wherein
R7 is —CF3 or —CHF2; and wherein
R8 is
and wherein
R9 is Br, Cl, F, I, or H;
with the following provisos:
when R4 is F: R2 is not —CH3 or F; R3 is not —CH3, —CN, F, Cl, or —OCH3; R5 is not —CH3, F, Cl, or —OCH3; and R6 is not —CH3 or F;
when R4 is Cl: R2 is not F; R3 is not F or —CN; R5 is not F, —CN, or —C(O)N(CH3)2, R6 is not —CF3 or F; D is not nitrogen; and either R5 is —C(O)NH2 or one of R2, R3, R5, and R6 is —CH3;
when R4 is —CH3: R3 is not F; R5 is not F; and R5 and R6 do not form a pyrimidine together with the atoms at d and e;
when R4 is —OCH3: R2 is not F; R3 is not Cl or —OCH3, R5 is not Cl or —OCH3; and R6 is not F or —CF3;
when R4 is —CN: R2 is not F; R3 is not Cl, F, or —OCH3, R5 is not Cl, F, or —OCH3; and R6 is not F;
when R4 is —OCH2CH3: R3 is not Cl or F; R5 is not Cl or F; and R6 is not —CF3;
when R4 is
R3 is not H or F; and R5 is not H or F;
when R4 is
at least one of R2, R3, R5, and R6 is not H;
when R4 is
R3 is not F; and R5 is not F;
when R2 is F: R3 is not —OCH3 or F; R5 is not —CN; and at least one of R3, R4, R5, and R6 is not H;
when R2 is Cl: R3 is not F;
when R2 is —CH3: R3 is not Cl; at least one of R3, R4, R5, and R6 is not —CH3; and R4 and R5 do not form a pyrazolyl with the atoms at c and d;
when R3 is —OCH3: R2 is not F; and R6 is not F;
when R3 is F: R2 is not —OCH3; and X is not
when R3 is Cl: R5 is not Cl; R is not benzyl; and R12 is not benzyl;
when R5 is Cl, R6 is not —CH3; R is not benzyl; and R12 is not benzyl;
when R5 is F or —OCH3: R6 is not F;
when R6 is F: at least one of R2, R3, R4, and R5 is not H;
when R3 and R5 are H: R11 is not cyclopropyl; and R12 is not cyclopropyl;
when R9 is Cl, R1 is not an amide group;
when B is nitrogen and A and D are carbon: R4 may not be —CN or
when R7 is —CHF2 and R4 is
then R4 does not have the absolute stereochemistry
and
wherein, when R8 is
then the following provisos are in effect:
when R4 is F: at least one of R2, R3, R5, and R6 is not H; R3 is not C(O)N(CH3)2; and R5 is not C(O)N(CH3)2;
when R4 is Cl: at least one of R2, R3, R5, and R6 is not H;
when R3 is F: R4 is not C(O)NHCH2CH2CH2CH3, C(O)N(CH3)2, C(O)NHCH2CH2CH3, or C(O)NHC(CH3)3;
R4 is not C(O)NHCH2CH2CH2OH, C(O)NHCH(CH3)2, —CN, or
R1 is not
R5 is not
R3 is not
when R2 is F: R5 is not —C(O)NH2;
when R2 is —CH3, R4 and R5 do not form a pyrazole with atoms at c and d; and
when B is nitrogen, R3 and R4 do not form an optionally substituted imidazole with the atoms at b and c; and
wherein, when R8 is
then following provisos are in effect:
R4 is not —CH3, —C(O)NHCH2CH2OH, —NHC(O)CH(CH3)2, or
when R4 is C(O)NHCH3, at least one of R2, R3, R5, and R6 is not H;
when R4 is —OCH3: R3 is not F or —CH3; and R5 is not F or —CH3;
when R4 is
R3 is not Cl; and R5 is not Cl;
when R4 is —C(O)NHCH(CH3)2 or —C(O)N(CH2CH3)2: at least one of R3 and R5 is not H;
R5 is not —C(O)NH2; and
R6 is not —CF3, comprising:
condensing a compound of formula V
and a compound of formula VI
to form a compound of formula XV
reacting a compound of formula XV with a triflouromethylsulfonylation reagent to provide a compound of formula XVI
and
(1) reducing a compound of formula XVI to form a compound of formula XVII
and subjecting a compound a formula XVII to Suzuki cross-coupling conditions with a boronate
to form a compound of formula (I);
or
(2) subjecting a compound of formula XVI to Suzuki cross-coupling conditions with a boronate
to form a compound of formula XIV
and reducing a compound of formula XIV to form a compound of formula (I).

### Claim 60 (depends on 59)

The method of claim 59, further comprising isolating a compound of formula IX
and isolating a compound of formula X

### Claim 61 (depends on 59)

The method according to claim 59, wherein the compound of formula (I) is a compound of formula (IV),
or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof or mixture of stereoisomers thereof, wherein: R7a is H or F; and wherein
Ring A is:
wherein Y1 and Y2 are independently selected from the group consisting of —CH2— and —CH2CH2—, and wherein each of Y1 and Y2 is optionally substituted by C1-3 alkyl;
wherein X1, X2, and X3 are independently selected from the group consisting of —CH— and N;
wherein X1, X2, and X3 are independently selected from the group consisting of —CH— and N;
wherein X is N or —CH— optionally substituted by —CH3, F, or Cl, and
wherein R9 is —C(O)Z, wherein Z is 2,3-dihydroxypropylamine; a five to seven member cyclic diamine that is optionally bridged or optionally substituted at a carbon atom with a lower alkyl; a seven to ten member bicyclodiamine; a seven to eleven member spirodiamine; —NH substituted with a four to seven member cyclic amine optionally substituted with —NH2—OH; —CH2NHR, wherein R is H or lower alkyl; —NH substituted with a seven to eleven member spiroalkane optionally substituted with —NH2; or
R9 is CH3NHC(O)—, and a carbon atom on the aryl ring to which R9 is attached is substituted with one of —CH3, F, or Cl; R9 is (CH3)2CHNHC(O)—, and a carbon atom on the aryl ring to which R9 is attached is substituted with one of —CH3, F, or Cl; or R9 is (CH3)3CNHC(O)— and a carbon atom on the aryl ring to which R9 is attached is substituted with one of —CH3, F, or Cl; or
R9 is
wherein the piperazine is optionally bridged or substituted with lower alkyl and R10 is H or —CH3; or
R9 is
wherein n is 1-3 and the cyclic diamine is optionally bridged or substituted with lower alkyl; or
R9 is
wherein n is 1-4; or
R9 is —NHC(O)NH2, —CH2C(O)NH— wherein the nitrogen is substituted with a four to seven member cyclic amine; —CH2—C(O)— wherein the carbonyl is substituted with a seven to ten member bicyclodiamine; and a four to seven member cyclic amine substituted with —CH2C(O)NH2; or
wherein X is N or —CH— wherein the C is optionally substituted by —CH3, F, or Cl, and wherein
R10 is —C(O)NH— wherein the nitrogen is substituted by a four to seven member cyclic amine; —C(O)— substituted by a seven to ten member bicyclodiamine; —C(O)— substituted by a seven to eleven member spirodiamine; pyrazole; [1,2,4]oxadiazole optionally substituted by —CH3 on a carbon atom of the oxadiazole; —NHC(O)CH3; —CH2— substituted by a piperazine; —CH2— substituted by a piperazine including a methyl substituent; —C(O)— substituted by a five to seven member cyclic diamine; —C(O)NHCH2— wherein the —CH2— is substituted by azetidine; or —C(O)— substituted with a five to seven member cyclic amine wherein the amine includes an —NH2 substituent; or
cyanophenyl; isoquinoline; cyclohexene substituted with —NH2 at the 4′ position; 1,4-dimethylindazole-5-yl; 1,6-dimethylindazole-5-yl; cyclohexene substituted with spiropiperidine at the 4′ position; 1-piperidinopyrazole; or o-methoxypyridine.

### Claim 62 (depends on 59)

The method according to claim 59, wherein the isolating is by chiral, high performance liquid chromatography or by diastereomeric crystallization.

### Claim 63 (depends on 59)

The method according to claim 59, wherein R8 is
